US Pharma MarketingAustralia approves first-in-class Niktimvo for later-line cGVHD
Australia approves first-in-class Niktimvo for later-line cGVHD is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Specialised Therapeutics’ Niktimvo (axatilimab) was registered in the Australian Register of Therapeutic Goods for later-line cGVHD.
Source: Pharmaceutical Technology